跳转至内容
Merck
  • Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy.

Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy.

Journal of neuroimmunology (2014-09-30)
Lamprini Skriapa, Paraskevi Zisimopoulou, Nikolaos Trakas, Eirini Grapsa, Socrates J Tzartos
摘要

Antibodies against MuSK seem to be the pathogenic factor in approximately 5-8% of myasthenia gravis (MG) patients. We aim to develop an antigen-specific therapy in which only MuSK antibodies will be removed from patients' plasma using MuSK extracellular domain (MuSK-ECD) as immunoadsorbent. We showed that two different immunoadsorbents, very efficiently and selectively depleted the MuSK antibodies from all tested sera, were stable during the procedure and were reusable. Furthermore, animal experiments showed that the treatment has no toxic effects to the animals. We conclude that the MuSK-ECD-mediated immunoadsorption can be used as an efficient antigen-specific therapy for MuSK-MG.

材料
货号
品牌
产品描述

Sigma-Aldrich
环磷酰胺 一水合物, bulk package
Sigma-Aldrich
环磷酰胺 一水合物, ISOPAC®
Supelco
环磷酰胺 一水合物, analytical standard
Supelco
4-叔辛基苯酚单氧化物 溶液, 10 μg/mL in acetone, analytical standard